JPMorgan lowered the firm’s price target on Solid Biosciences (SLDB) to $11 from $13 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences price target lowered to $14 from $16 at Citi
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays
- Solid Biosciences Reports Q3 2025 Results and Clinical Progress